[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma-following-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma-following-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100453166","phase-1-topical-infliximab-in-eyes-with-penetrating-keratoplasty-100453166",false,"NCT05180994","Topical Infliximab in Eyes With Penetrating Keratoplasty","Inclusion Criteria:\n\n* Age between 18 and 80 years;\n* First corneal transplant surgery;\n* Capable of providing informed consent;\n* Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Past corneal transplant (any technique);\n* Advanced glaucoma or macular disease;\n* Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);\n* Malignancy diagnosed in the past 5 years (any kind);\n* Demyelinating disease;\n* History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);\n* Pregnancy or breastfeeding;\n* Allergy to infliximab or to a compound of its topical formulation;\n* Significant anomaly of complete blood count or hepatic enzymes;\n* Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.","ALL","18 Years","80 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.",[27],"Glaucoma Following Surgery","RECRUITING","2026-04-23",{"date":31,"type":32},"2026-04-27","ACTUAL",{"date":34,"type":32},"2022-05-01",{"date":36,"type":20},"2028-03-01",{"name":38,"class":39},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER"]